What MDMA-Assisted Therapy Actually Is — and What It Isn't

MDMA-assisted therapy is a structured, clinician-delivered treatment in which a dose of MDMA (3,4-methylenedioxymethamphetamine) is taken as part of a psychotherapy session, with the patient's blood pressure and heart rate monitored, and with therapy sessions before and after. It is not a medication you take at home, and it is not a party drug used in a clinic.

The distinction matters because almost every confusion about this treatment comes from collapsing the two halves. The drug and the therapy are tested together, delivered together, and studied together. Remove either half and you no longer have the thing that was studied.

What the medicine does in the room

MDMA is a sympathomimetic amine that raises activity in serotonin, dopamine and norepinephrine systems, and it reliably increases feelings of trust, emotional closeness and reduced fear of the material being discussed. In clinical trials it is given in one to three sessions, typically a few weeks apart, in a treatment room rather than a ward.

The American Journal of Psychiatry's review of the field describes the target of that drug effect precisely: the medicine is used to make an otherwise overwhelming conversation tolerable, not to produce relief by itself. Patients in trials are asked to revisit traumatic memories with a therapist present — the same exposure work that has long been used in trauma therapy, but with the fear response chemically turned down.

What the therapists do

Trials have used a two-therapist model, usually one man and one woman, who stay in the room for the whole session. Their work divides into three phases:

• Preparation. One or more sessions before the dosing day, in which the therapists build the relationship, review the person's history and safety screening, and agree on what the session will work on.
• The dosing session. Typically six to eight hours. The therapists monitor physiological signs, keep the room safe and quiet, and support the patient as difficult material surfaces. Eyeshades and music are commonly used.
• Integration. A session in the days after, where the experience is talked through and translated into changes the person can carry into daily life.

The Australian and New Zealand guideline body treats this three-phase structure as the definition of the treatment, not a description of one clinic's style. Its clinical practice guidance for MDMA-assisted psychotherapy for PTSD specifies preparation, the MDMA session, and integration as the required format.

Why the drug alone is not the treatment

Every trial that has shown benefit compared MDMA plus the same psychotherapy against placebo plus the same psychotherapy. In the confirmatory Phase 3 programme run by MAPS, both arms received identical therapy — which means the therapy itself was doing substantial work in both groups. That is the honest way to read the results: people improve on trauma therapy, and the addition of MDMA appears to help more of them improve, and improve further.

It also explains why regulators have pushed back so hard. When the FDA declined the application in August 2024 and asked for a new randomised, double-blind Phase 3 trial plus an independent audit of study records, the objection was about how the combination had been tested — not a claim that the drug does nothing.

What it is not

• Not a daily medication. There is no prescription you fill. The dose is administered under supervision on set days.
• Not a stand-alone injection or infusion. Unlike ketamine clinics, the medicine is inseparable from the therapy hours around it.
• Not an approved medicine in most countries. In the United States it remains unapproved; in Australia it is available only through a tightly controlled authorised-prescriber route.
• Not a cure that works for everyone. A large share of participants in trials still met criteria for PTSD afterwards.

Who it is being studied for

Post-traumatic stress disorder is the indication with Phase 3 data, and it is the only one regulators have formally considered. Separate studies are now exploring major depressive disorder, social anxiety, and PTSD alongside alcohol use disorder. Those are earlier-stage questions, and this site labels them as such.

If you are weighing this treatment for yourself, the practical question is not "does MDMA work" but "is the full package — screening, preparation, supervised dosing, integration — legally and safely available to me, and am I in the group it was tested in." The rest of our Explainers section walks through each of those.